BRIEF published on 10/01/2024 at 00:56, 1 month 20 days ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:45, 1 month 20 days ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 1 month 20 days ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 month 20 days ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 3 months 15 days ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
PRESS RELEASE published on 08/05/2024 at 19:18, 3 months 15 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF published on 06/05/2024 at 07:05, 5 months 16 days ago Minutes of the general meeting of Valerio Therapeutics Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE published on 06/05/2024 at 07:00, 5 months 16 days ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
BRIEF published on 05/22/2024 at 20:51, 5 months 29 days ago Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE published on 05/22/2024 at 20:46, 5 months 29 days ago Inside Information / Other news releases Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
Published on 11/21/2024 at 13:00, 37 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 37 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 37 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 37 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 37 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 1 hour 2 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 22 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 39 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 17 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 52 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 52 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
